Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design

Abstract

A randomized, double-blind, parallel-group trial testing if semaglutide is superior to placebo when added to standard care for preventing major adverse cardiovascular events in patients with CVD and overweight or obesity but no diabetes.

Citation
Ryan DH, Lingvay I, Colhoun HM, et al. Am Heart J 2020;229:61–9.